Pharmaceutical Executive: March 2025

View the Pharmaceutical Executive March 2025 issue in an interactive format.

As coverage in Pharmaceutical Executive’s March issue reinforces, AI's connections and permutations are seemingly touching all parts of the industry—and only growing.

Immunotherapy pioneer Mark Frohlich, MD, CEO of Indapta Therapeutics, discusses the promise of harnessing natural killer cells to reshape treatment for cancer and autoimmune disease.

A look at the current landscape and how young companies can set the stage for product launch.

Market dynamics boost the need and urgency for more sophisticated benchmarking strategies.

What biopharma companies need to know about this evolving regulatory pathway.

Heather Gervais, CEO of Osso VR, discusses how technological advancements in VR are solving problems for pharmaceutical sales reps.

Traditional approaches to HCP segmentation are no longer sufficient. The challenge now is to maintain personalization at scale while managing large territories and diverse customer bases.